LG Life Sciences to conduct phase I trial of novel diabetic agent

Published: 2006-10-27 06:56:00
Updated: 2006-10-27 06:56:00
LG Life Sciences announced on October 25 that it will conduct Phase I test of a new dipeptidyl peptidase IV (LC15-0444) for the treatment of type II diabetes.

In type II diabetes, either the pancreas does not produce sufficient insulin or the body fails to respond properly to insulin.

LG di...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.